# Bioequivalence of Vildagliptin Tablet Manufactured in China Compared to Imported Vildagliptin Tablet in Chinese Healthy Volunteers

> **NCT00414947** · PHASE1 · COMPLETED · sponsor: **Novartis** · enrollment: 30 (—)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Vildagliptin (LAF237)

## Key facts

- **NCT ID:** NCT00414947
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 30 (—)
- **Last updated:** 2007-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00414947

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00414947, "Bioequivalence of Vildagliptin Tablet Manufactured in China Compared to Imported Vildagliptin Tablet in Chinese Healthy Volunteers". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00414947. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*